I-Hui Wu

I-Hui Wu

Auto-generated profile, based on publicly available information

I-Hui Wu

Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSShian-Ying Sung
Shian-Ying Sung
CLChia-Hui Liao
Chia-Hui Liao
HWHsun-Pai Wu
Hsun-Pai Wu
WHWan-Chi Hsiao
Wan-Chi Hsiao
IWI-Hui Wu
I-Hui Wu
CHChia-Ling Hsieh
Chia-Ling Hsieh
Bone marrow-derived mesenchymal stem cells (MSCs) are able to migrate to tumors, where they promote tumorigenesis and cancer metastasis. However, the molecular phenotype of the recruited MSCs at the tumor microenvironment and the genetic programs underlying their role in cancer progression remains largely unknown. By using a three-dimensional rotary wall vessel coculture system in which human MSCs were grown alone or in close contact with LNCaP, C4-2 or PC3 prostate cancer cell lines, we established in vitro matched pairs of normal and cancer-associated MSC derivatives to study the stromal response of MSCs to prostate cancer. We observed that prostate cancer-associated MSCs acquired a higher potential for adipogenic differentiation and exhibited a stronger ability to promote prostate cancer cell migration and invasion compared with normal MSCs both in vitro and in experimental animal models. The enhanced adipogenesis and the pro-metastatic properties were conferred by the high levels of IL-6 secretion by cancer-associated MSCs and were reversible by functionally inhibiting of IL-6. We also found that IL-6 is a direct target gene for the let-7 microRNA, which was downregulated in cancer-associated MSCs. The overexpression of let-7 via the transfection of let-7 precursors decreased IL-6 expression and repressed the adipogenic potential and metastasis-promoting activity of cancer-associated MSCs, which was consistent with the inhibition of IL-6 3′UTR luciferase activity. Conversely, the treatment of normal MSCs with let-7 inhibitors resulted in effects similar to those seen with IL-6. Taken together, our data demonstrated that MSCs co-evolve with prostate cancer cells in the tumor microenvironment, and the downregulation of let-7 by cancer-associated MSCs upregulates IL-6 expression. This upregulation triggers adipogenesis and facilitates prostate cancer progression. These findings not only provide key insights into the molecular basis of tumor-stroma interactions but also pave the way for new treatments for metastatic prostate cancer.

1 June 2018 in Cell Reports
Verified
Journal Article
Open access
EPEmile S. Pinarbasi
Emile S. Pinarbasi
AKAndrey L. Karamyshev
Andrey L. Karamyshev
ETElena B. Tikhonova
Elena B. Tikhonova
IWI-Hui Wu
I-Hui Wu
HHHenry Hudson
Henry Hudson
PTPhilip J. Thomas
Philip J. Thomas
Cells have evolved quality control pathways to prevent the accumulation of improperly localized proteins, which are often toxic. One of these pathways, regulation of aberrant protein production (RAPP), recognizes aberrant secretory proteins during translation and degrades the associated mRNA. Here, we demonstrate endogenous RAPP substrates. Haploinsufficiency of the secretory protein progranulin (GRN) is associated with the neurodegenerative disease frontotemporal lobar degeneration (FTLD). Our results show FTLD-associated GRN mutations W7R and A9D disrupt co-translational interaction with a targeting factor, signal recognition particle (SRP). This triggers RAPP and initiates specific mRNA degradation. Conversely, wild-type GRN and the naturally occurring polymorphism V5L GRN are efficiently expressed and secreted. Thus, RAPP plays a role in the molecular pathology of A9D GRN and W7R GRN.

16 September 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
SSShian-Ying Sung
Shian-Ying Sung
IWI-Hui Wu
I-Hui Wu
PCPei-Hsin Chuang
Pei-Hsin Chuang
JPJohn A. Petros
John A. Petros
HWHsi-Chin Wu
Hsi-Chin Wu
CHChia-Ling Hsieh
Chia-Ling Hsieh
The L1 cell adhesion molecule (L1CAM) has been implicated in tumor progression of many types of cancers, but its role in prostate cancer and its application in targeted gene therapy have not been investigated. Herein, we demonstrated that the L1CAM was expressed in androgen-insensitive and highly metastatic human prostate cancer cell lines. The correlation between L1CAM expression and prostate cancer metastasis was also validated in serum samples of prostate cancer patients. Knockdown of L1CAM expression in prostate cancer cells by RNA interference significantly decreased their aggressive behaviors, including colony formation, migration and invasion in vitro, and tumor formation in a metastatic murine model. These anti-malignant phenotypes of L1CAM-knockdown cancer cells were accompanied by G0/G1 cell cycle arrest and suppression of matrix metalloproteinase (MMP)-2 and MMP-9 expression and nuclear factor NF-κB activation. In vivo targeting of L1CAM expression using liposome-encapsulated L1CAM siRNAs effectively inhibited prostate cancer growth in mouse bone, which was associated with decreased L1CAM expression and cell proliferation by tumor cells. These results provide the first evidence for L1CAM being a major contributor to prostate cancer metastasis and translational application of siRNA-based L1CAM-targeted therapy.

15 November 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
SHShiao-Chen Hung
Shiao-Chen Hung
IWI-Hui Wu
I-Hui Wu
SHShui-Sang Hsue
Shui-Sang Hsue
CLChia-Hui Liao
Chia-Hui Liao
HWHsien-Chi Wang
Hsien-Chi Wang
CHChia-Ling Hsieh
Chia-Ling Hsieh